Mono Vaccines (Epstein – Barr virus) Market Overview, Industry Top Manufactures, Market Size, Industry Growth Analysis and Forecast: 2027

Mono Vaccines (Epstein – Barr virus) Market report provides key enumeration on the Market status of the Mono Vaccines (Epstein – Barr virus) manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. The research was conducted using an objective combination of primary and secondary information including inputs from key participants in the Mono Vaccines (Epstein – Barr virus) industry. It delivers important information to identify and analyse the market need, market Growth and competition.

Market-research techniques encompass qualitative techniques. The report helps the user to strengthen decisive power to plan their strategic moves to launch or expand their businesses by offering them a clear picture of this market. Mono Vaccines (Epstein – Barr virus) Market Research Report gives current competitive analysis and also valuable insights to clients/industries, which will assist them to prepare a new strategy to expand or penetrate in a global Mono Vaccines (Epstein – Barr virus) Market.

Request Here Sample Copy Of Report

Monovaccine (Epstein-Barr virus) Market-Insights

Infectious mononucleosis also known as mono or kissing disease, which is caused by Epstein-Barr virus and commonly transmitted by saliva. The virus can also be spread through other ways such as by sharing drinks or utensils.

Epstein-Barr virus also known as human herpesvirus 4 is the causative agent of mono/kissing disease, and is one of eight known human herpes virus types in the herpes family. Moreover, according to the data published by Fred Hutchinson Cancer Research Center in 2018, Epstein–Barr virus infects around 9 out of 10 people, globally at some point in their lives.

The increasing research and development activities and funding by various organizations are expected to lead to the development of monovaccine in future, thereby fuelling the market growth over the forecast period. Various organizations are focusing on research and development of novel monovaccines or Epstein – Barr virus vaccines, which is expected to spur interest of industry players to conduct research and development in this area of high unmet needs.

For instance, in April 2018, researchers from Fred Hutchinson Cancer Research Center and the University of Washington developed a human antibody in laboratory that blocks infection by mono Epstein-Barr virus or EBV. The development of the antibody along with the site it targets, opens a new path to developing effective monovaccines.

Furthermore, various organizations are involved in granting funding to various universities for development of novel Epstein – Barr virus vaccine. Such funding and investments are expected to support the research and development of vaccines, thereby driving the market growth over the forecast period.

For instance, in 2017, University of Kansas School of Engineering and School of Pharmacy received US$ 1.8 million, five-year grant from the National Institutes of Health for conducting research, in order to develop effective vaccine for Epstein – Barr virus (EBV).

Among regions, North America and Europe are expected to be a potential regions for monovaccines over the forecast period.

Moreover, increasing prevalence of Epstein-Barr virus infection and disease associated with it is expected to propel growth of the global monovaccine (Epstein-Barr virus) market. For instance, according to data published by the Centers for Disease Control and Prevention (CDC) in 2018, Epstein-Barr virus (EBV) is one of the most common human viruses. According to the same source, it was estimated that around nine out of ten adults have antibodies that show that they have a current or past EBV infection, in the U.S.

Furthermore, in Europe, there is increasing number of research and development activities for the development of novel monovaccines and this is further expected to drive the market growth during the forecast period.

For instance, in March 2017, Cancer Research U.K. completed its phase 1b of clinical trials of Modified Vaccinia Ankara (MVA-EBNA1/LMP2) vaccine. It is indicated for the treatment of nasopharyngeal cancer patients with positive Epstein-Barr virus infection.

Moreover, in January 2019, researchers and scientists from the German Cancer Research Center developed a new strategy for a vaccine that targets different EBV virus life phases and exhibits potential to provide effective protection against EBV infection.

Such, initiatives from several organizations for development of novel monovaccines (Epstein – Barr virus) are expected to fuel the market growth.

Market Restraint

Currently, there is no approved EBV vaccine in the market. The major factor that is expected to hinder the monovaccine (Epstein-Barr virus) market growth include various barriers in the development and gaining regulatory approval for EBV vaccines.

Some of the barriers in development of an EBV vaccine include difficulty of in performing clinical trials, lack of knowledge of immune correlates for protection against EBV infection and disease, and limitations in animal models to study protection against EBV infection and disease.

Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/2002

Mono Vaccines (Epstein – Barr virus) Market – Competitive Landscape

Key players functioning in the global prosthetic liners market consists of Cancer Research UK, National Institutes of Health, Chinese University of Hong Kong, Genocea Biosciences, Inc., Dana-Farber Cancer Institute, German Cancer Research Institute, and University of Minnesota.

Main points in Mono Vaccines (Epstein – Barr virus) Market Report Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Mono Vaccines (Epstein – Barr virus) Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Mono Vaccines (Epstein – Barr virus) Industry Impact

Chapter 2 Global Mono Vaccines (Epstein – Barr virus) Competition by Types, Applications, and Top Regions and Countries
2.1 Global Mono Vaccines (Epstein – Barr virus) (Volume and Value) by Type
2.3 Global Mono Vaccines (Epstein – Barr virus) (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Mono Vaccines (Epstein – Barr virus) Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Mono Vaccines (Epstein – Barr virus) Market Analysis
Chapter 6 East Asia Mono Vaccines (Epstein – Barr virus) Market Analysis
Chapter 7 Europe Mono Vaccines (Epstein – Barr virus) Market Analysis
Chapter 8 South Asia Mono Vaccines (Epstein – Barr virus) Market Analysis
Chapter 9 Southeast Asia Mono Vaccines (Epstein – Barr virus) Market Analysis
Chapter 10 Middle East Mono Vaccines (Epstein – Barr virus) Market Analysis
Chapter 11 Africa Mono Vaccines (Epstein – Barr virus) Market Analysis
Chapter 12 Oceania Mono Vaccines (Epstein – Barr virus) Market Analysis
Chapter 13 South America Mono Vaccines (Epstein – Barr virus) Market Analysis
Chapter 14 Company Profiles and Key Figures in Mono Vaccines (Epstein – Barr virus) Business
Chapter 15 Global Mono Vaccines (Epstein – Barr virus) Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com